Nuvectis Pharma (NVCT) Total Current Liabilities (2021 - 2026)

Nuvectis Pharma has disclosed Total Current Liabilities across 6 years of filings, most recently posting $11.2 million for Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $11.2 million, up 21.58% year-over-year; the trailing twelve-month figure through Mar 2026 was $11.2 million (up 21.58% YoY), and the FY2025 annual result was $13.3 million, up 49.49% from the prior year.
• Total Current Liabilities came in at $11.2 million for Q1 2026 at Nuvectis Pharma, down from $13.3 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $13.3 million in Q4 2025 to a low of $2.7 million in Q2 2022.
• The 5-year median for Total Current Liabilities is $6.2 million (2022), against an average of $7.0 million.
• Across the five-year window, Total Current Liabilities surged 155.73% in 2022 and rose 12.9% in 2023, its largest moves.
• Nuvectis Pharma's Total Current Liabilities stood at $6.2 million in 2022, then rose by 12.9% to $7.0 million in 2023, then rose by 27.35% to $8.9 million in 2024, then surged by 49.49% to $13.3 million in 2025, then fell by 15.93% to $11.2 million in 2026.
• The last three Total Current Liabilities figures came in at $11.2 million (Q1 2026), $13.3 million (Q4 2025), and $11.6 million (Q3 2025), per Business Quant data.